The prevalence of schizophrenia is higher in patients with type 2 diabetes mellitus (T2DM) compared with the general population, according to results of a study recently published in European Psychiatry.

Investigators conducted a retrospective cohort study using insurance claims data from enrollees in the Taiwan National Health Insurance Program. The study cohort comprised patients with T2DM and schizophrenia (n = 532), patients with T2DM without schizophrenia (n=61,835), and patients without either condition, termed the “general population” (n=715,756). Participants with schizophrenia had a record of at least 1 outpatient or inpatient service claim for a principal diagnosis of schizophrenia; patients with T2DM had at least 2 service claims for ambulatory care or 1 service claim for inpatient care for a principal diagnosis of T2DM. Investigators also captured numerous demographic characteristics including age, sex, residential area and urbanization level, income, comorbidities, duration of diabetes mellitus, and Charlson Comorbidity Index (CCI).

The 1-year prevalence rate of schizophrenia was significantly higher in the T2DM group (0.85%) compared with the general population (0.56%; P <.0001). The 1-year prevalence rate of schizophrenia remained high among patients with T2DM who had received oral antidiabetic therapy (0.84%) compared with the general population (P <.0001). Among patients with T2DM who had not received antidiabetic therapy, the prevalence of schizophrenia was even higher (0.91%). Following multiple logistic regression analyses, a high prevalence of schizophrenia was observed in patients with T2DM who were <60 years of age, particularly among those between the ages of 31 and 40 (adjusted odds ratio [AOR], 3.56; 95% CI, 1.42-8.93; P =.0069) and between the ages of 41 and 50 years (AOR, 3.98; 95% CI, 1.61-9.83; P =.0027). Additionally, among individuals with T2DM, higher prevalence of schizophrenia was associated with residence in eastern Taiwan (AOR, 2.29; 95% CI, 1.51-3.45; P <.0001), lower income levels (AORs between 5.33-13.74), and CCI >2 (AOR, 1.43; 95% CI, 1.05-1.94; P =.022).


Continue Reading

Related Articles

These data suggest that the prevalence of schizophrenia is higher in patients with T2DM compared with the general population, and that this prevalence may increase based on a number of covariates. Clinicians should utilize these results to leverage appropriate care to at-risk patients.

Reference

Huang C-J, Hsieh H-M, Tu H-P, Jiang H-J, Wang P-W, Lin C-H. Schizophrenia in type 2 diabetes mellitus: prevalence and clinical characteristics. Eur Psychiatry. 2018;54:102-108.